Salvage Cryotherapy in Recurrent Prostate Cancer - Full Text View

Sponsors and Collaborators:	University of Colorado at Denver and Health Sciences Center Endocare, Inc.
Information provided by:	University of Colorado at Denver and Health Sciences Center
ClinicalTrials.gov Identifier:	NCT00824928

Purpose

To provide a systemic, uniform and user-friendly tool for collection of data on prostate cancer salvage cryotherapy in a multicenter setting. The goal is to learn more about the short and long term efficacy and safety of this procedure. Ultimately the data analysis will serve as a robust guidance instrument for improving upon the utilization of this procedure for the treatment of patients with recurrent (LRD) prostate cancer.

Condition	Intervention
Recurrent Prostate Cancer	Procedure: Cryoablation / Cryotherapy

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study

Further study details as provided by University of Colorado at Denver and Health Sciences Center:

Primary Outcome Measures:

Biochemical failure after treatment (defined as nadir PSA value + 2 ng/dl documented in the postoperative period). [ Time Frame: 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Percentage change in QoL scores (EPIC) if available [ Time Frame: 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician ] [ Designated as safety issue: No ]
Percentage change in AUA-symptom score (also referred to as IPSS score) [ Time Frame: 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician ] [ Designated as safety issue: No ]
Percentage change in erectile dysfunction as measured by Sexual Health Inventory for men score (SHIM also referred to as IIEF score) [ Time Frame: 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician ] [ Designated as safety issue: No ]
Percentage change in urinary symptoms (continence score) [ Time Frame: 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	800
Study Start Date:	January 2007

Groups/Cohorts	Assigned Interventions
Observational Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy	Procedure: Cryoablation / Cryotherapy Salvage Cryoablation of the prostate

Eligibility

Ages Eligible for Study:	30 Years to 80 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Academic Institutions and Community Urologic Oncology Clinics in the United States of America and the United Kingdom

Criteria

Inclusion Criteria:

Read & understand informed consent related to this study including consenting and HIPPA authorization
Undergone salvage cryotherapy of the prostate for recurrent prostate cancer

Exclusion Criteria:

Patients who underwent radical prostatectomy as their primary therapy or other significant surgery (except prostatic biopsy)
Patients with clinically confirmed distant metastasis (unless deemed beneficial by the treating physician)
Any previous major rectal surgery
Clinically significant lower urinary tract or rectal anomalies
Existing urethral, rectal, or bladder fistulae

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824928

Contacts

Contact: Al Barqawi, MD

720-848-0922

al.barqawi@ucdenver.edu

Locations

United States, California
Prostate Institute of America	Recruiting
Ventura, California, United States, 93003
Contact: Duke Bahn, MD 805-585-3082
USC/Norris Comprehensive Cancer Center and Hospital	Recruiting
Los Angeles, California, United States, 90089-9181
Contact: Clinical Trials Office - USC/Norris Comprehensive Cancer Cente 323-865-0451
United States, Colorado
University of Colorado at Denver and Health Sciences Center	Recruiting
Aurora, Colorado, United States, 80045
Contact: Al Barqawi, MD 720-848-0922 al.barqawi@ucdenver.edu
United States, Georgia
Emory Clinic, Emory University Hospital	Recruiting
Atlanta, Georgia, United States, 30322
Contact: Peter T. Nieh, MD 404-778-4898
United States, Illinois
Rush University Medical Center	Recruiting
Chicago, Illinois, United States, 60612
Contact: Charles F. McKiel, MD 312-563-3447
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center	Recruiting
Indianapolis, Indiana, United States, 46202-5289
Contact: Clinical Trials Office - Indiana University Cancer Center 317-274-2552
United States, Michigan
Barbara Ann Karmanos Cancer Institute	Recruiting
Detroit, Michigan, United States, 48201-1379
Contact: Clinical Trials Office - Barbara Ann Karmanos Cancer Institute 313-576-8426
United States, Nebraska
UNMC Eppley Cancer Center at the University of Nebraska Medical Center	Recruiting
Omaha, Nebraska, United States, 68198
Contact: Rob Bayer, R.N. 402-559-4235
United States, Rhode Island
Rhode Island Hospital/Warren Alpert Medical School of Brown University	Recruiting
Providence, Rhode Island, United States, 02904
Contact: Gyan Pareek, MD 401-272-7799
United States, Tennessee
University of Tennessee Cancer Institute - Memphis	Recruiting
Memphis, Tennessee, United States, 38104
Contact: Clinical Trials Office - University of Tennessee Cancer Insti 901-448-3303
United States, Virginia
Urology of Virginia, Sentara Medical Group	Recruiting
Norfolk, Virginia, United States, 23502
Contact: Director of Research 757-457-5166

Sponsors and Collaborators

University of Colorado at Denver and Health Sciences Center

Endocare, Inc.

Investigators

Study Chair:	Al Barqawi, MD	University of Colorado at Denver and Health Sciences Center
Study Chair:	David Crawford, MD	University of Colorado at Denver and Health Sciences Center

More Information

No publications provided

Responsible Party:	University of Colorado at Denver and Health Sciences Center ( Albaha Barqawi, MD )
Study ID Numbers:	06-1040
Study First Received:	January 15, 2009
Last Updated:	January 22, 2009
ClinicalTrials.gov Identifier:	NCT00824928 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Colorado at Denver and Health Sciences Center:

Prostate Cancer
Recurrent Prostate Cancer
Prostate Cancer Recurrence
Radiation Failure
Salvage Cryotherapy

Study placed in the following topic categories:

Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms

Genital Diseases, Male
Prostatic Neoplasms
Recurrence

Additional relevant MeSH terms:

Disease Attributes
Neoplasms
Pathologic Processes
Neoplasms by Site
Prostatic Diseases

Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms
Recurrence

ClinicalTrials.gov processed this record on May 07, 2009